Novo's weekly diabetes drug clears another Phase III hurdle

Novo Nordisk's ($NVO) in-development weekly diabetes treatment met its goals in a second Phase III trial, beating AstraZeneca's ($AZN) Bydureon in a 56-week study. In the trial, Novo's semaglutide charted a statistically significant improvement in blood sugar over AstraZeneca's weekly treatment in patients with Type 2 diabetes. The study is part of a 6-trial effort designed to support global approvals for semaglutide. In the first late-stage trial, the subcutaneous injection got about 73% of patients to their goal blood sugar levels, beating out placebo's 25%. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.